1. Home
  2. MLYS vs COTY Comparison

MLYS vs COTY Comparison

Compare MLYS & COTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Coty Inc.

COTY

Coty Inc.

HOLD

Current Price

$2.69

Market Cap

2.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
COTY
Founded
2019
1904
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
MLYS
COTY
Price
$25.85
$2.69
Analyst Decision
Strong Buy
Hold
Analyst Count
7
16
Target Price
★ $48.67
$4.18
AVG Volume (30 Days)
1.2M
★ 4.6M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $5,806,600,000.00
Revenue This Year
N/A
$0.10
Revenue Next Year
N/A
$1.29
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$22.30
$1.82
52 Week High
$47.65
$4.47

Technical Indicators

Market Signals
Indicator
MLYS
COTY
Relative Strength Index (RSI) 39.48 49.71
Support Level $22.36 $2.45
Resistance Level $31.36 $2.71
Average True Range (ATR) 1.48 0.10
MACD -0.40 -0.00
Stochastic Oscillator 5.09 73.97

Price Performance

Historical Comparison
MLYS
COTY

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About COTY Coty Inc.

Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.

Share on Social Networks: